TITLE

Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones

AUTHOR(S)
Hofmann, A. F.
PUB. DATE
May 2005
SOURCE
Gut;May2005, Vol. 54 Issue 5, p575
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the implication of treating acromegalic patients with octreotide. In acromegalic patients, octreotide administration suppresses the release of growth hormone and insulin growth factor by the pituitary and results in clinical improvement.
ACCESSION #
16886324

 

Related Articles

  • Acromegaly. Collison, Kiren; Wass, John AH // GP: General Practitioner;11/17/2006, p30 

    The article presents the author's views on various factors related to acromegaly, a rare medical condition occurring equally in males and females. Acromegaly is caused by excessive secretion of growth hormone and insulin-like growth factor-1. Acromegaly may be difficult to identify in the...

  • Growth hormone: its measurement and the need for assay harmonization. Wood, Peter // Annals of Clinical Biochemistry;Sep2001, Vol. 38 Issue 5, p471 

    Serum human growth hormone (hGH) assays show a wide range in bias and in cut-off values for provocative tests, which vary from 13.5 to 35-40 mU/L when they have been established. Studies using novel hGH assays show that methods that are absolutely specific for 22-kDa hGH may not identify...

  • Rheumatoid arthritis masquerading as acromegaly recurrence: report of two cases. Aydın, Yusuf; Coşkun, Hülya; Kır, Seher; Yazici, Selma; Kudaş, Özlem; Güngör, Adem // Rheumatology International;Sep2012, Vol. 32 Issue 9, p2913 

    Acromegaly is a chronic endocrinopathy characterized by hypersecretion of growth hormone (GH) and consequently of insulin-like growth factor-1 (IGF-1). The arthropathy in acromegaly is the most frequent and important cause of morbidity and functional disability in acromegaly. Rheumatoid...

  • Treatment of Acromegaly with the Growth Hormone—Receptor Antagonist Pegvisomant. Trainer, Peter J.; Drake, William M.; Katznelson, Laurence; Freda, Pamela U.; Herman-Bonert, Vivien; van der Lely, A.J.; Dimaraki, Eleni V.; Stewart, Paul M.; Friend, Keith E.; Vance, Mary Lee; Besser, G. Michael; Thorner, Michael O.; Parkinson, Craig; Klibanski, Anne; Powell, Jeffrey S.; Barkan, Ariel L.; Sheppard, Michael C.; Maldonado, Mario; Rose, D. Roderick; Clemmons, David R. // New England Journal of Medicine;04/20/2000, Vol. 342 Issue 16, p1171 

    Background: Patients with acromegaly are treated with surgery, radiation therapy, and drugs to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have adverse effects. Pegvisomant is a genetically engineered growth hormone–receptor antagonist that blocks...

  • Lanreotide Autogel®: A Review of its Use in the Management of Acromegaly. Croxtall, Jamie D.; Scott, Lesley J. // Drugs;2008, Vol. 68 Issue 5, p711 

    Lanreotide Autogel (ATG) [Somatuline Depot] is a novel, long-acting preparation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of...

  • Pharmacological Therapy for Acromegaly: A Critical Review. Muller, Alex F.; van der Lely, Aart Jan // Drugs;2004, Vol. 64 Issue 16, p1817 

    The treatment of acromegaly has changed considerably over the last few decades. In the late 1970s, the introduction of the dopamine receptor agonists made it possible to reduce growth hormone (GH) secretion by somatotropinomas for the first time. Thereafter, the introduction of the somatostatin...

  • Pituitary.  // Current Medical Literature: Growth, Growth Hormone, & Metabolism;2009, Vol. 2 Issue 3, p83 

    The article discusses several studies on pituitary hormones. One study focuses on the prevalence of growth hormone (GH) and other anterior pituitary hormone deficiencies in adults with nonsecreting pituitary micro-adenomas and normal serum insulin-like growth factor-1 (IGF-1) levels. Another...

  • Growth Hormone and Insulin-Like Growth Factor-I as an Endocrine Axis in Alzheimer's Disease. Gómez, José Manuel // Endocrine, Metabolic & Immune Disorders - Drug Targets;Jun2008, Vol. 8 Issue 2, p143 

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment with insidious onset. Neuropathological analysis of AD-affected brains reveals extensive atrophy and an accumulation of neurofibrillary tangles. Taken together, the neurochemical changes in...

  • Growth hormone as an early embryonic growth and differentiation factor. Sanders, Esmond; Harvey, Steve // Anatomy & Embryology;Nov2004, Vol. 209 Issue 1, p1 

    In this review we consider the evidence that growth hormone (GH) acts in the embryo as a local growth, differentiation, and cell survival factor. Because both GH and its receptors are present in the early embryo before the functional differentiation of pituitary somatotrophs and before the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics